Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 17Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 23Esophageal Squamous Cell Carcinoma 22Stomach Neoplasms 14Colorectal Neoplasms 13Liver Neoplasms 7Esophageal Neoplasms 6Rectal Neoplasms 5Pancreatic Neoplasms 4Cholangiocarcinoma 4Locally Advanced Rectal Cancer 3Biliary Tract Neoplasms 3Advanced Pancreatic Cancer 3Turcot syndrome 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Microsatellite Stable Metastatic Colorectal Cancer 2Klatskin Tumor 2Gallbladder Neoplasms 2Early Low Rectal Cancer 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of the Stomach 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Carcinoma of Esophagus 1Sarcoma 1Radiotherapy 1Pathologic Complete Response 1Pancreatic Cancer Metastatic 1

Interventions

pembrolizumab 49Nivolumab 21Cisplatin 11Cetuximab 11Carboplatin 10Paclitaxel 8Gemcitabine 8Docetaxel 8atezolizumab 7Ipilimumab 7Cyclophosphamide 7spartalizumab 6durvalumab 6Fluorouracil 6Capecitabine 6fludarabine 5avelumab 5Albumin-Bound Paclitaxel 5cemiplimab 4Trastuzumab 4Taxes 4Oxaliplatin 4Leucovorin 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3tisotumab vedotin 3aldesleukin 3Specimen Handling 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × toripalimab × Gastrointestinal × Clear all
NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
401 enrolled 1 FDA
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡